Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

The Global Health Innovative Technology reports new funding partnerships

June 6, 2016

Phase II/III trial of VLA-43 does not confirm previously seen positive vaccine effect

June 6, 2016

FORGE Life Science announces antiviral compounds

June 6, 2016

Achaogen awarded funding for phase III EPIC study

June 6, 2016

NanoViricides enters partnership to further FluCide-I program

June 3, 2016

GeoVax's Ebola vaccine demonstrates complete protection against EBV challenge

June 2, 2016

Actelion Pharmaceuticals patents antibacterials

June 2, 2016

FDA grants fast track designation for VT-1129

June 2, 2016

FDA approves Teflaro in pediatric patients

June 1, 2016

Soligenix's SGX-943 gets FDA fast track designation

June 1, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...